Recombinant Newcastle disease virus expressing H9 HA protects chickens against heterologous avian influenza H9N2 virus challenge |
| |
| Institution: | 1. Department of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, USA;2. Department of Virology, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt;3. Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA;4. Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA;5. Innovation Team for Pathogen Ecology Research on Animal Influenza Virus, Department of Avian Infectious Disease, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, China;6. Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA;1. UQ Child Health Research Centre, School of Medicine, The University of Queensland, Brisbane, Queensland, Australia;2. Drug Department, Saudi Food and Drug Authority, Saudi Arabia;3. School of Public Health, The University of Queensland, Brisbane, Queensland, Australia;4. Communicable Diseases Branch, Queensland Health, Brisbane, Queensland, Australia;1. Key Laboratory of Animal Epidemiology and Zoonosis, Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing, 100193, China;2. Animal Health Supervision Institute of Xinjiang Uygur Autonomous Region, Urumqi, 830023, China;3. Department of Computational Biology, St. Jude Children’s Research Hospital, Memphis, TN 38105-3678, USA;4. Eccles Institute of Human Genetics, Salt Lake City, UT 84112, USA;5. Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105-3678, USA;1. Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Muang, Nonthaburi, Thailand;2. National Institute of Health, Department of Medical Sciences, Ministry of Public Health, Muang, Nonthaburi, Thailand;3. Department of Virology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan;4. Kanonji Institute, The Research Foundation for Microbial Diseases of Osaka University, Kanonji, Kagawa, Japan;5. Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Izumisano, Osaka, Japan;6. Ina Laboratory, Medical & Biological Laboratories Corporation, Ltd., Ina, Nagano, Japan;7. Food and Drug Administration, Ministry of Public Health, Muang, Nonthaburi, Thailand;8. Japan Science and Technology Agency/Japan International Cooperation Agency, Science and Technology Research Partnership for Sustainable Development (JST/JICA, SATREPS), Tokyo, Japan;1. Bio-pharmaceutical Lab, College of Life Science, Northeast Agricultural University, Harbin 150030, China;2. School of Food Science and Technology, Jiangnan University, State Key Laboratory of Food Science and Technology, Wuxi, China;3. Harbin Veterinary Research Institute Harbin, China;1. Anses (French Agency for Food, Environmental and Occupational Health Safety), Ploufragan/Plouzané Laboratory, Avian and Rabbit Virology Immunology and Parasitology Unit (VIPAC), B.P. 53, 22440 Ploufragan, France;2. Anses (French Agency for Food, Environmental and Occupational Health Safety), Ploufragan/Plouzané Laboratory, Avian Experimentation and Breeding Service (SELEAC), B.P. 53, 22440 Ploufragan, France |
| |
| Abstract: | In order to produce an efficient poultry H9 avian influenza vaccine that provides cross-protection against multiple H9 lineages, two Newcastle disease virus (NDV) LaSota vaccine strain recombinant viruses were generated using reverse genetics. The recombinant NDV-H9Con virus expresses a consensus-H9 hemagglutinin (HA) that is designed based on available H9N2 sequences from Chinese and Middle Eastern isolates. The recombinant NDV-H9Chi virus expresses a chimeric-H9 HA in which the H9 ectodomain of A/Guinea Fowl/Hong Kong/WF10/99 was fused with the cytoplasmic and transmembrane domain of the fusion protein (F) of NDV. Both recombinant viruses expressed the inserted HA stably and grew to high titers. An efficacy study in chickens showed that both recombinant viruses were able to provide protection against challenge with a heterologous H9N2 virus. In contrast to the NDV-H9Chi virus, the NDV-H9Con virus induced a higher hemagglutination inhibition titer against both NDV and H9 viruses in immunized birds, and efficiently inhibited virus shedding through the respiratory route. Moreover, sera collected from birds immunized with either NDV-H9Con or NDV-H9Chi were able to cross-neutralize two different lineages of H9N2 viruses, indicating that NDV-H9Con and NDV-H9Chi are promising vaccine candidates that could provide cross-protection among different H9N2 lineage viruses. |
| |
| Keywords: | Influenza Recombinant NDV LaSota viruses H9N2 Cross-protection |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
